within Pharmacolibrary.Drugs.ATC.A;

model A16AB04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.043333333333333335,
    adminDuration  = 600,
    adminMass      = 0.001,
    adminCount     = 1,
    Vd             = 0.003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Agalsidase beta is a recombinant form of human alpha-galactosidase A enzyme used as enzyme replacement therapy for patients with Fabry disease, a rare X-linked lysosomal storage disorder. It helps clear globotriaosylceramide (GL-3) accumulation in various tissues and is approved for long-term treatment of Fabry disease in adults and children.</p><h4>Pharmacokinetics</h4><p>Population PK study in adult male and female patients with Fabry disease receiving 1 mg/kg agalsidase beta as a 2-hour intravenous infusion every 2 weeks.</p><h4>References</h4><ol><li><p>Berstein, V, et al., &amp; Coppola, S (2024). Comparative pharmacokinetics and pharmacodynamics of two formulations of agalsidase beta (agalsidase Biosidus) and Fabrazyme® by intravenous infusion in healthy male volunteers. <i>Molecular genetics and metabolism reports</i> 41 101149–None. DOI:<a href=&quot;https://doi.org/10.1016/j.ymgmr.2024.101149&quot;>10.1016/j.ymgmr.2024.101149</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39435314/&quot;>https://pubmed.ncbi.nlm.nih.gov/39435314</a></p></li><li><p>Keating, GM, &amp; Simpson, D (2007). Agalsidase Beta: a review of its use in the management of Fabry disease. <i>Drugs</i> 67(3) 435–455. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200767030-00007&quot;>10.2165/00003495-200767030-00007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17335299/&quot;>https://pubmed.ncbi.nlm.nih.gov/17335299</a></p></li><li><p>Wu, YS, et al., &amp; Johnson, FK (2021). Migalastat Tissue Distribution: Extrapolation From Mice to Humans Using Pharmacokinetic Modeling and Comparison With Agalsidase Beta Tissue Distribution in Mice. <i>Clinical pharmacology in drug development</i> 10(9) 1075–1088. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.941&quot;>10.1002/cpdd.941</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33876577/&quot;>https://pubmed.ncbi.nlm.nih.gov/33876577</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A16AB04;
